[go: up one dir, main page]

FR2926463B1 - Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale - Google Patents

Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale

Info

Publication number
FR2926463B1
FR2926463B1 FR0850389A FR0850389A FR2926463B1 FR 2926463 B1 FR2926463 B1 FR 2926463B1 FR 0850389 A FR0850389 A FR 0850389A FR 0850389 A FR0850389 A FR 0850389A FR 2926463 B1 FR2926463 B1 FR 2926463B1
Authority
FR
France
Prior art keywords
preventing
treating cancer
epithelial origin
cancer metastases
aminopeptidase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0850389A
Other languages
English (en)
Other versions
FR2926463A1 (fr
Inventor
Pierre Roux
Toledo Marion De
Laureline Roger
Jean Paul Leonetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0850389A priority Critical patent/FR2926463B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA2712339A priority patent/CA2712339A1/fr
Priority to JP2010542670A priority patent/JP2011509982A/ja
Priority to EP09706702A priority patent/EP2234610A2/fr
Priority to PCT/FR2009/050081 priority patent/WO2009095583A2/fr
Priority to CN2009801053395A priority patent/CN101951905A/zh
Priority to US12/812,501 priority patent/US20110046154A1/en
Publication of FR2926463A1 publication Critical patent/FR2926463A1/fr
Application granted granted Critical
Publication of FR2926463B1 publication Critical patent/FR2926463B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
FR0850389A 2008-01-22 2008-01-22 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale Active FR2926463B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0850389A FR2926463B1 (fr) 2008-01-22 2008-01-22 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
JP2010542670A JP2011509982A (ja) 2008-01-22 2009-01-21 上皮起源からのガン転移を防ぎ又は処置する為のアミノペプチダーゼインヒビター又はアザインドール化合物の使用
EP09706702A EP2234610A2 (fr) 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
PCT/FR2009/050081 WO2009095583A2 (fr) 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
CA2712339A CA2712339A1 (fr) 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
CN2009801053395A CN101951905A (zh) 2008-01-22 2009-01-21 氨肽酶抑制剂或氮杂吲哚化合物用于预防或治疗上皮来源的癌转移的用途
US12/812,501 US20110046154A1 (en) 2008-01-22 2009-01-21 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0850389A FR2926463B1 (fr) 2008-01-22 2008-01-22 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale

Publications (2)

Publication Number Publication Date
FR2926463A1 FR2926463A1 (fr) 2009-07-24
FR2926463B1 true FR2926463B1 (fr) 2010-08-13

Family

ID=39708890

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0850389A Active FR2926463B1 (fr) 2008-01-22 2008-01-22 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale

Country Status (7)

Country Link
US (1) US20110046154A1 (fr)
EP (1) EP2234610A2 (fr)
JP (1) JP2011509982A (fr)
CN (1) CN101951905A (fr)
CA (1) CA2712339A1 (fr)
FR (1) FR2926463B1 (fr)
WO (1) WO2009095583A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2654428B1 (fr) * 2010-12-22 2018-02-14 The Trustees of Columbia University in the City of New York Modulateurs de l'histone acétyltransférase et leurs utilisations
CN102212511A (zh) * 2011-03-31 2011-10-12 山东大学 定点突变的嗜热菌f3因子重组蛋白及其应用
CN105541806A (zh) * 2015-12-25 2016-05-04 中国药科大学 巴比妥酸类化合物、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
EP1337854A2 (fr) * 2000-11-14 2003-08-27 Novartis AG Methode de criblage de composes antiproliferatifs et methode permettant d'inhiber une croissance tumorale
EP1382349A1 (fr) * 2001-04-27 2004-01-21 Nippon Kayaku Kabushiki Kaisha Immunotherapie supplementaire pouvant etre utilisee apres une ablation pulmonaire liee a un cancer
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
JP2008516903A (ja) * 2004-10-14 2008-05-22 エフ．ホフマン−ラ ロシュ アーゲー 抗癌剤としての新規アザインドールチアゾリノン
WO2006050076A1 (fr) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
FR2926463A1 (fr) 2009-07-24
US20110046154A1 (en) 2011-02-24
CN101951905A (zh) 2011-01-19
WO2009095583A3 (fr) 2010-03-11
WO2009095583A2 (fr) 2009-08-06
EP2234610A2 (fr) 2010-10-06
JP2011509982A (ja) 2011-03-31
CA2712339A1 (fr) 2009-08-06

Similar Documents

Publication Publication Date Title
EP2063882A4 (fr) Inhibiteurs de kinase pour la prévention ou le traitement d'une infection
EP2119477A4 (fr) Composition pour le traitement de la xérostomie ou de la sécheresse de la bouche
EP2643480A4 (fr) Procédés et/ou utilisation de conjugués d'oligonucléotide pour des essais et des détections
FR14C0050I1 (fr) Compositions et leurs utilisations pour le traitement de la sclerose en plaques
EP2531225A4 (fr) Procédés d'utilisation de composés inorganiques hydrosolubles pour implants
EP1994181A4 (fr) Identification et utilisation de novopeptides pour le traitement du cancer
EP2488953A4 (fr) Masquage d'interruptions pour processeurs multicoeurs
EP2591354A4 (fr) Composés et procédés pour l'inhibition du transport de phosphate
FR2938202B1 (fr) Traitement de surface pour adhesion moleculaire
EP2658580A4 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP2619184A4 (fr) Inhibiteurs de déubiquitinase et leurs procédés d'utilisation
EP2875826A4 (fr) Composition pour la prévention ou le traitement d'une sepsie
EP2185173A4 (fr) Utilisation de phosphatases pour traiter des neuroblastomes et des médulloblastomes
EP2272817A4 (fr) Inhibiteur de pai-1
EP2182804A4 (fr) Procédés de traitement d'une dépendance
EP2488025A4 (fr) Inhibiteurs de sépiaptérine réductase pour le traitement de la douleur
EP2568999A4 (fr) Acth pour le traitement de la sclérose latérale amyotrophique
EP2590510A4 (fr) Composés et procédés pour l'inhibition du transport de phosphate
EP2590965A4 (fr) Composés et procédés pour l'inhibition du transport de phosphate
ME02999B (fr) Utilisation d'inhibiteurs de vap-1 pour traiter des lésions fibreuses
EP2203057A4 (fr) Procédés et compositions pour le traitement ou la prévention d'états inflammatoires
EP2414765A4 (fr) Système de nettoyage pour le nettoyage d'une tuyauterie
EP2402431A4 (fr) Agent pour la prévention ou l'amélioration de l'obésité
EP2651439A4 (fr) Compositions et procédés pour le traitement ou la prévention d'une infection par l'adénovirus 36 humain
EP1986619A4 (fr) Utilisation de phosphatase pour traiter des tumeurs surexprimant n-cor

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18